Biogen | BIIB - Loan Capital


Biogen reported $6.29B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 285.82M 639K Sep/2024
Amgen USD 50B 2.43B Dec/2025
Bayer EUR 31.83B 877M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Incyte USD 30.2M 5.17M Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 2.45B Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Teva Pharmaceutical Industries USD 14.99B 1.78B Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025